Imatinib use extended

The licence for Glivec (imatinib) has been extended to include the treatment of adult patients with: - newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy, or as monotherapy in patients with relapsed or refractory disease. - unresectable dermatofibrosarcoma protuberans or patients with recurrent and/or metastatic disease who are not eligible for surgery.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

A photo of the white and pink Luforbec inhaler.

First metered-dose inhaler certified 'carbon-neutral'

Luforbec (beclometasone/formoterol) has been certified...

Male clinician in white coat showing female patient how to use IQoro device.

Training device for reflux and dysphagia available on NHS

A neuromuscular training device for patients with reflux-based...